Longevity Medicine in Singapore: From Research to Practical Screening

The word “longevity” has a problem. It has been adopted so broadly — by wellness influencers, supplement companies, IV drip clinics, and biohacking communities — that it has become difficult to separate what is evidence-based from what is marketing.

This matters, because underneath the noise, there is a serious and growing field of preventive medicine that is genuinely changing how clinicians think about long-term health. The research is real. The markers are measurable. The interventions are, for the most part, surprisingly unglamorous.

Longevity medicine is the clinical practice of identifying and intervening on health risks years or decades before they become disease — using advanced biomarkers, imaging, and functional assessments that go beyond what standard screening offers. This article is our attempt to explain longevity medicine as we practice it — what it is, what it is not, and what a grounded, clinical approach looks like in a Singapore primary care setting.

What is longevity medicine?

Longevity medicine is, at its core, a reframing of the question that medicine asks. Traditional medicine asks: “Is something wrong?” Longevity medicine asks: “Where is this heading — and what can we change now to alter that trajectory?”

In Singapore, standard preventive care — including the Ministry of Health Screen for Life programme — focuses on established disease detection: cholesterol, blood glucose, colorectal and cervical cancer screening. These are valuable, but they are designed for population-level risk, not individual trajectory tracking.

The distinction matters more than it might initially appear. Standard preventive care is calibrated to detect disease that is already present or imminent. A normal blood pressure reading, a normal fasting glucose, a normal cholesterol panel — these tell you that disease has not yet developed to a detectable threshold. They do not tell you whether you are moving toward that threshold.

Longevity medicine tracks a broader set of markers, at earlier time points, with the goal of identifying physiological changes a decade or more before clinical disease emerges. It is interested in trajectories — not snapshots.

The field is sometimes described in terms of the distinction between lifespan — how long you live — and healthspan — how many of those years you live in good health, with full physical and cognitive function. Most people, given a genuine choice, would prioritise healthspan. Most healthcare is still primarily designed to extend lifespan, with less attention to the quality of the years added.

Why does early detection matter?

One of the most useful frameworks in longevity medicine is the idea of a physiological trajectory from wellness toward disease — and the recognition that most chronic diseases that shorten or diminish life have detectable precursors that appear years before clinical diagnosis.

Type 2 diabetes does not appear overnight. Insulin resistance typically precedes it by a decade or more — measurable through fasting insulin and HOMA-IR long before blood glucose rises into a diagnostic range. Cardiovascular disease develops against a background of years of elevated inflammatory markers, accumulating arterial plaque, and worsening vascular function. Many cancers have detectable biological signals — circulating tumour DNA in blood — before they are visible on imaging.

The clinical implication is clear: the earlier you identify where a patient is on a given trajectory, the more opportunity there is to intervene before the trajectory becomes irreversible. A small course correction at 40 is far easier than managing established disease at 60.

Which markers actually matter?

The honest answer is that longevity medicine is still establishing its evidence base for some markers. What follows are those with the strongest and most consistent evidence.

Advanced cardiovascular markers

Standard lipid panels miss important cardiovascular risk. Lipoprotein(a) — a genetically inherited cardiovascular risk factor affecting roughly one in five people — is not included in routine panels. ApoB provides a more precise measure of atherogenic particle burden than LDL cholesterol alone. These markers add significantly to cardiovascular risk prediction beyond what a standard panel captures.

Insulin resistance markers

Fasting insulin and HOMA-IR identify insulin resistance years before blood glucose rises into a prediabetic range. Given that insulin resistance underlies type 2 diabetes, fatty liver, polycystic ovarian syndrome, and significant cardiovascular risk — and given that it is highly modifiable through lifestyle — identifying it early has meaningful clinical value.

Inflammatory markers

hsCRP and homocysteine reflect chronic low-grade inflammation — the kind that smoulders silently and contributes to cardiovascular disease, metabolic dysfunction, and accelerated biological ageing. Both are modifiable. Both are absent from most standard health screens.

Hormonal health

Sex hormones — testosterone, oestradiol, and in women, AMH — decline with age and play important roles in metabolic health, bone density, cognitive function, and wellbeing. Tracking these longitudinally allows hormonal ageing to be managed proactively rather than reactively. DHEAS, an adrenal hormone, provides an additional window into biological age and adrenal reserve.

Physical function

VO2 max — cardiorespiratory fitness — is one of the strongest predictors of all-cause mortality in the evidence base. Grip strength and the 30-second sit-to-stand test are validated predictors of functional decline. DEXA body composition distinguishes visceral fat from lean muscle mass — a distinction that BMI cannot make. These physical function markers provide information that blood tests cannot.

How is longevity medicine different from “anti-ageing”?

The term “anti-ageing” covers a spectrum — from evidence-based preventive medicine to aesthetic procedures to clinics offering unvalidated interventions. The distinction matters, and we want to be direct about it.

We are also conscious that longevity medicine itself is not free from hype. Some markers are tracked more because they are interesting than because there is strong evidence for intervention. Some protocols are adopted from academic research before their clinical utility is established. Part of our job as clinicians is to distinguish what the evidence supports from what is speculative — and to be honest when the evidence is limited or still developing.

How does longevity medicine work in a GP setting?

There is a perception that longevity medicine belongs in specialist clinics or concierge practices. We think that is the wrong model. The GP-patient relationship — built over years of continuity, trust, and contextual understanding — is precisely the right setting for longitudinal health tracking.

What longevity medicine looks like in practice at Advantage Medical Group:

1. Baseline assessment — a comprehensive screen covering vascular, metabolic, inflammatory, hormonal, and physical function markers. This establishes where a patient sits on each longevity dimension at a given point in time.
2. Physician-led interpretation — results are reviewed with a doctor in a 60-minute consultation. Not a summary report. A conversation about what the numbers mean in the context of this patient’s history, family background, and goals.
3. A clear plan — not every marker requires intervention. The consultation distinguishes what needs active management, what needs monitoring, and what the patient can address themselves through lifestyle change.
4. Annual review — the same markers tracked year on year. The trend is the clinical signal. Is cardiovascular fitness improving? Is insulin resistance resolving? Is inflammation decreasing?

This is not a concierge service. It does not require ongoing membership or monthly check-ins. It is a structured annual assessment within a primary care setting — available to anyone who wants a more complete picture of their long-term health trajectory.

How do you take the first step?

The most common thing we hear from patients who have completed a longevity assessment is that they wish they had done it sooner — not because anything alarming was found, but because knowing their numbers gave them something to work with. A direction. A baseline against which future progress can be measured.

If you are reading this and finding yourself curious — about Lp(a), about VO2 max, about insulin resistance, about where your hormonal health is heading — that curiosity is worth following. The markers exist. The tests are available. The interpretation is what primary care is for.

Longevity medicine will continue to evolve. The evidence base will deepen. Some of what we currently track will prove more or less useful than we think. We will update our protocols accordingly — and we will tell you when we do. That is, we think, the honest way to practice in a field that is still maturing.